RADA16 for Aquablation Day Case
Launched by NYU LANGONE HEALTH · Apr 28, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The RADA16 clinical trial is looking at a new treatment called PuraStat to see how it helps reduce bleeding (hematuria) after a procedure called Aquablation, which is used to treat urinary problems in men caused by an enlarged prostate. The main goal is to find out if using PuraStat can help patients have less bleeding after their surgery, which may allow them to go home on the same day instead of staying overnight in the hospital.
To participate in this trial, you need to be a man who is scheduled for Aquablation due to lower urinary tract symptoms from benign prostatic hyperplasia (BPH). If you choose to join, you can expect to have your bleeding monitored after the procedure and learn if PuraStat helps improve your recovery. It's important to note that this trial is not yet recruiting participants, and you would need to agree to participate by signing a consent form.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • • Any man undergoing Aquablation for LUTS due to BPH
- Exclusion Criteria:
- • • Unwilling to sign consent
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Christopher Kelly, MD
Principal Investigator
NYU Langone Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported